HENLIUS (02696): The Biologics License Application (BLA) for Hanbeite (Bevacizumab injection) has been accepted by the Food and Drug Administration (FDA) of the United States.

Fosun Pharma (02696) announced that its independently developed biological product, Hanbeite (Bevacizumab Injection) ("Hanbeite"), has had its Biologics License Application ("BLA") accepted by the U.S. Food and Drug Administration ("FDA"). The indications covered by this application include: (1) metastatic colorectal cancer; (2) first-line treatment with carboplatin and paclitaxel for unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer; (3) recurrent adult glioblastoma; (4) combination with Interferon- for metastatic renal cell carcinoma; (5) epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and (6) combination with paclitaxel and cisplatin, or paclitaxel and topotecan for persistent, recurrent, or metastatic cervical cancer.